HALO · Halozyme Therapeutics, Inc. · Analyst Estimates
$100.27
-0.40 (-0.40%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$11.43B
Shares
114.01M
Volume · Nov 13
2.28M
Avg daily vol (3M)
2.24M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for Halozyme Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Pull consensus estimates through the analyst estimates API or MCP →Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-11-14 12:51 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
8.73
|
8.89
|
9.04
|
6
|
8.84
|
8.58
|
8.58
|
8.58
|
1
|
1
|
2
|
3
|
|
Revenue
USD
Publication date not stated |
1.88B
|
1.90B
|
1.93B
|
9
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
9.60
|
10.59
|
11.48
|
5
|
10.68
|
10.39
|
10.39
|
10.39
|
— | — |
1
|
2
|
|
Revenue
USD
Publication date not stated |
2.09B
|
2.18B
|
2.35B
|
8
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
2.48
|
2.63
|
2.78
|
6
|
2.64
|
2.60
|
2.60
|
2.60
|
0
|
2
|
0
|
2
|
|
Revenue
USD
Publication date not stated |
540.00M
|
551.49M
|
574.32M
|
7
|
— | — | — | — | — | — | — | — |
Q ending 2027-03-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
2.32
|
2.33
|
2.34
|
3
|
2.33
|
2.34
|
2.34
|
2.34
|
0
|
0
|
2
|
2
|
|
Revenue
USD
Publication date not stated |
478.00M
|
488.72M
|
499.43M
|
2
|
— | — | — | — | — | — | — | — |
Key facts
CIK
1159036
CUSIP
40637H109
13F (30d)
619 filings
569 filers
Visit website
Investor relations